Objective:

To evaluate the effect of high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the severity of allergic rhinitis and the quality of life of patients affected by this condition.

Methods:

Randomized, double-blind, placebo-controlled study. Both groups received pharmacological treatment with intranasal fluticasone and allergy immunotherapy during the escalation phase. The control group received a placebo, while the experimental group received EPA capsules: 1340 mg and DHA: 924 mg daily for 2 months.

Results:

The experimental group included 10 patients (2 men and 8 women), with a mean age of 31.5 ± 15.1 years, while the control group included 12 patients (5 men and 7 women) with a mean age of 27.4 ± 14.3 years (p = 0.56 for age). After the intervention, the median quality of life and nasal symptom scores were also similar between both groups (p = 0.668 and p = 0.920, respectively), with no significant differences.

Conclusion:

Supplementation with high doses of EPA and DHA in patients with persistent allergic rhinitis was safe, but there was no evidence of a reduction in severity or improvement in quality of life compared to the placebo group. Further clinical trials are required to clarify its potential role as an adjunctive strategy.

        · resumen en Español     · texto en Español     · Español ( pdf )